Clinical trial
Transitioning From Cyclosporine to Alefacept in Psoriasis
NCT00143806 · University of Medicine and Dentistry of New Jersey, Other · Completed
Key facts
| NCT number | NCT00143806 |
|---|---|
| Title | Transitioning From Cyclosporine to Alefacept in Psoriasis |
| Official title | Investigator-Initiated, Use Study of Alefacept (Amevive) in Combination With Tapering Doses of Cyclosporine in Patients With Moderate to Severe Psoriasis |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Transitioning patients from cyclosporine to alefacept |
| Enrollment | 13 |
| Start date | Oct 1, 2003 |
| Completion | May 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Jan 5, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: